Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

884 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Apoptotic and Immune Restoration Effects of Ganoderic Acids Define a New Prospective for Complementary Treatment of Cancer.
Radwan FF, Perez JM, Haque A. Radwan FF, et al. J Clin Cell Immunol. 2011 Dec 11;S3:4. doi: 10.4172/2155-9899.S3-004. J Clin Cell Immunol. 2011. PMID: 23336088 Free PMC article.
While current research has revealed GAs' role in inducing apoptosis of cancer cells with a much lower toxicity to healthy cells, little information is available on their in vitro and/or in vivo immune activities. ...We also discuss other new approaches for exploiting the a …
While current research has revealed GAs' role in inducing apoptosis of cancer cells with a much lower toxicity to healthy cells, litt …
Induction of apoptosis and immune response by all-trans retinoic acid plus interferon-gamma in human malignant glioblastoma T98G and U87MG cells.
Haque A, Das A, Hajiaghamohseni LM, Younger A, Banik NL, Ray SK. Haque A, et al. Cancer Immunol Immunother. 2007 May;56(5):615-25. doi: 10.1007/s00262-006-0219-6. Epub 2006 Sep 1. Cancer Immunol Immunother. 2007. PMID: 16947022
Patients die within a year of diagnosis despite the use of available treatment strategies such as surgery, radiotherapy, and chemotherapy. Thus, there is a critical need to find a novel therapeutic strategy for treating this disease. Here, we have investigate …
Patients die within a year of diagnosis despite the use of available treatment strategies such as surgery, radiotherapy, and chemothe …
Invariant chain modulates HLA class II protein recycling and peptide presentation in nonprofessional antigen presenting cells.
Haque A, Hajiaghamohseni LM, Li P, Toomy K, Blum JS. Haque A, et al. Cell Immunol. 2007 Sep;249(1):20-9. doi: 10.1016/j.cellimm.2007.10.005. Epub 2007 Dec 11. Cell Immunol. 2007. PMID: 18067883 Free PMC article.
By contrast, fibroblast lines expressing Ii favor exogenous peptides binding directly to cell surface class II molecules without a need for ligand internalization. ...
By contrast, fibroblast lines expressing Ii favor exogenous peptides binding directly to cell surface class II molecules without a ne …
HLA-DM negatively regulates HLA-DR4-restricted collagen pathogenic peptide presentation and T cell recognition.
Amria S, Hajiaghamohseni LM, Harbeson C, Zhao D, Goldstein O, Blum JS, Haque A. Amria S, et al. Eur J Immunol. 2008 Jul;38(7):1961-70. doi: 10.1002/eji.200738100. Eur J Immunol. 2008. PMID: 18506881
While the etiology of rheumatoid arthritis remains unknown, type II collagen (CII) is a candidate autoantigen. An immunodominant pathogenic epitope from this autoantigen, CII(261-273), which binds to HLA-DR4 and activates CD4+ T cells, has been identified. The non-classica …
While the etiology of rheumatoid arthritis remains unknown, type II collagen (CII) is a candidate autoantigen. An immunodominant path …
Insights into the Role of GILT in HLA Class II Antigen Processing and Presentation by Melanoma.
Norton DL, Haque A. Norton DL, et al. J Oncol. 2009;2009:142959. doi: 10.1155/2009/142959. Epub 2009 Nov 24. J Oncol. 2009. PMID: 20016802 Free PMC article.
This review also summarizes our current knowledge on GILT and highlights a novel mechanism of GILT-mediated immune responses against melanoma cells. At the end, we propose a strategy employing GILT in the development of a potential whole cell vaccine for comb …
This review also summarizes our current knowledge on GILT and highlights a novel mechanism of GILT-mediated immune responses against …
Burkitt lymphoma: pathogenesis and immune evasion.
God JM, Haque A. God JM, et al. J Oncol. 2010;2010:516047. doi: 10.1155/2010/516047. Epub 2010 Oct 5. J Oncol. 2010. PMID: 20953370 Free PMC article.
Burkitt lymphoma (BL) is a highly malignant B-cell tumor associated with Epstein-Barr Virus (EBV) infection. Although BL can be effectively treated in adults and children, leading to high survival rates, its ability to mask itself from the immune system makes BL an intrigu …
Burkitt lymphoma (BL) is a highly malignant B-cell tumor associated with Epstein-Barr Virus (EBV) infection. Although BL can be effec …
Molecular alterations in glioblastoma: potential targets for immunotherapy.
Haque A, Banik NL, Ray SK. Haque A, et al. Prog Mol Biol Transl Sci. 2011;98:187-234. doi: 10.1016/B978-0-12-385506-0.00005-3. Prog Mol Biol Transl Sci. 2011. PMID: 21199773 Free PMC article. Review.
A better understanding of the molecular interactions among glioblastoma tumors, host immune cells, and the tumor microenvironment may give rise to novel integrated approaches for the simultaneous control of tumor escape pathways and the activation of antitumor immune respo
A better understanding of the molecular interactions among glioblastoma tumors, host immune cells, and the tumor microenvironment may
Mechanisms regulating enhanced human leukocyte antigen class II-mediated CD4 + T cell recognition of human B-cell lymphoma by resveratrol.
Radwan FF, Zhang L, Hossain A, Doonan BP, God JM, Haque A. Radwan FF, et al. Leuk Lymphoma. 2012 Feb;53(2):305-14. doi: 10.3109/10428194.2011.615423. Epub 2011 Oct 24. Leuk Lymphoma. 2012. PMID: 21854084 Free PMC article.
Resv also altered endolysosomal cathepsins (Cat S, B and D) and a thiol reductase (GILT), increasing HLA class II-mediated antigen (Ag) processing in B-cell lymphomas and their subsequent recognition by CD4 + T cells. ...
Resv also altered endolysosomal cathepsins (Cat S, B and D) and a thiol reductase (GILT), increasing HLA class II-mediated antigen (A …
Enhancement of HLA class II-restricted CD4+ T cell recognition of human melanoma cells following treatment with bryostatin-1.
Zhao D, Amria S, Hossain A, Sundaram K, Komlosi P, Nagarkatti M, Haque A. Zhao D, et al. Cell Immunol. 2011;271(2):392-400. doi: 10.1016/j.cellimm.2011.08.007. Epub 2011 Aug 18. Cell Immunol. 2011. PMID: 21903207 Free PMC article.
Bryostatin-1, a protein kinase C (PKC) activator, has been considered as a potent chemotherapeutic agent in a variety of in vitro tumor models. ...These data suggest that bryostatin-1 could be used as a chemo-immunotherapeutic agent for reducing tumori …
Bryostatin-1, a protein kinase C (PKC) activator, has been considered as a potent chemotherapeutic agent in a variety o …
884 results
Jump to page
Feedback